Physician profile
Ashley Cheek
NPI 1518525419
$960.20
in general payments reported to CMS, 2019-2025
18 companies · $62.90 in 2025
The $62.90 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $109 · 2023: $437 · 2024: $215 · 2025: $62.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $186.00 | 2022-2024 | |
| Novo Nordisk INC | $138.71 | 2021-2024 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $97.83 | 2021 | |
| Lilly USA, LLC | $78.34 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $74.23 | 2022-2025 | |
| Astellas Pharma US INC | $63.51 | 2023-2025 | Veozah |
| Pfizer INC. | $50.95 | 2023-2024 | |
| Eisai INC. | $35.72 | 2023-2024 | |
| Glaxosmithkline, LLC. | $34.23 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $33.82 | 2023 | Rexulti |
| Abbott Laboratories | $31.19 | 2024 | Freestyle Libre 3 |
| Organon LLC | $26.29 | 2023 | Nexplanon |
| Genentech USA, INC. | $23.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.72 | 2024 | Andexxa |
| Novartis Pharmaceuticals Corporation | $18.09 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.75 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.80 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $13.09 | 2023 | Verquvo, Belsomra, Steglatro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Cheek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.